RXEI Stock Overview

Engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. More details

RXEI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($12K)

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

RxElite, Inc. Competitors

Ampio Pharmaceuticals

OTCPK:AMPE

US$11.4k

Juva Life

OTCPK:JUVA.F

US$16.4k

BZAM

OTCPK:BZAM.F

US$270.0

Veritas Farms

OTCPK:VFRM

US$343.8k

Price History & Performance

Summary of share price highs, lows and changes for RxElite
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	1,566.67%
5 Year Change	9,900.00%
Change since IPO	-99.99%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	RXEI	US Pharmaceuticals	US Market
7D	0%	0.1%	-0.5%
1Y	n/a	0.6%	21.1%

Return vs Industry: Insufficient data to determine how RXEI performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how RXEI performed against the US Market.

Price Volatility

Is RXEI's price volatile compared to industry and market?
RXEI volatility
RXEI Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	5.9%
10% most volatile stocks in US Market	18.2%
10% least volatile stocks in US Market	3.0%

Stable Share Price: RXEI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine RXEI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	www.piramalcriticalcare.com

RxElite, Inc. engages in the development, manufacture, and marketing of generic prescription drug products in specialty generic markets. Its products include Sterile Liquid Dose products that consist of generic ophthalmic products in unit and multi-dose presentations, sterile unit dose inhalation respiratory products, and injectable drugs. The company, through its subsidiaries, also manufactures active pharmaceutical ingredients for pharmaceutical companies in the United States, Europe, and Asia.

RxElite, Inc. Fundamentals Summary

How do RxElite's earnings and revenue compare to its market cap?
RXEI fundamental statistics
Market cap	US$11.67k
Earnings (TTM)	-US$29.23m
Revenue (TTM)	US$10.44m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is RXEI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RXEI income statement (TTM)
Revenue	US$10.44m
Cost of Revenue	US$9.24m
Gross Profit	US$1.20m
Other Expenses	US$30.43m
Earnings	-US$29.23m

Last Reported Earnings

Sep 30, 2008

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did RXEI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 01:09
End of Day Share Price	2024/09/27 00:00
Earnings	2008/09/30
Annual Earnings	2007/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

RxElite, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.